Initial Beneficial Ownership · 3
Helus Pharma Inc.
Initial Beneficial Ownership
Structured filing — 3
form3.xml
Filing details
- Report period
- 2026-10-13
- Issuer
- Helus Pharma Inc.
- Issuer CIK
- 0001833141
- Trading symbol
- HELP
Reporting owner 1
- Name
- Lewis-Hall Freda C
- Reporting owner CIK
- 0001437909
- Relationship
- Director
- Address
- C/O HELUS PHARMA INC., 100 KING STREET W., SUITE 5600, TORONTO, ONTARIO, CANADA, A6, M5X 1C9
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Shares | 100,000 | D |
Table key
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|
| Options ("Right to Buy") | 5.99[F2] | [F1] | 2035-10-01 | Common Shares | 25,000 | I | Held by Intelmed, LLC[F3] |
| Restricted Share Units | [F5] | [F4] | [F4] | Common Shares | 25,000 | D |
Table key
- I
- Indirect
- D
- Direct
Footnotes
- F1
- The options vest quarterly over two years, commencing on December 31, 2025.↩ 1
- F2
- Converted from Canadian exercise price of C$8.39 using an exchange rate of C$1.40 = US$1.00.↩ 1
- F3
- Intelmed, LLC is a limited liability company owned and controlled by the reporting person.↩ 1
- F5
- Each RSU represents a right to receive one Issuer common share.↩ 1
Signature 1
- Signed
- /s/ Freda Lewis-Hall
- Date
- 2026-10-26